NF2 and meningioma: Combined Dasatinib and dual mTORC1/2 inhibition led to stronger growth suppression, suggesting co-targeting Eph RTK/SFK and mTORC1/2 pathways may benefit NF2-deficient meningiomas (Angus et al., 2018).